Clinical Trials Arena2d agobullish
J&J’s Intra-Cellular buy continues to bear fruit with Caplyta bipolar winJ&J acquired Intra-Cellular in 2025 for $14.6bn, making it the largest pharma M&A deal in 2025.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
150last 24h
878last 7d
146● bullish (7d)
96● bearish (7d)
214publishers